Renal Research Insitutue
New York, 10128, United States
NCT Number: NCT01252771
The study aims to investigate the concept of computer based Phosphate Kinetic Modeling (PKM) in the hemodialysis patient population. This computerized algorithm model was developed as a tool to aid physicians in controlling a hemodialysis patient's phosphate level. Once a subject consents to participate in the study, the subject's dietary phosphate intake will be estimated by the modeling program and the appropriate dose of the phosphate binder calcium acetate (PhosLo) will be recommended accordingly. If necessary, the Ca++ concentration of the dialysate will be changed to remove any excess calcium absorbed as the result of an increase in the PhosLo prescription to control phosphorus.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
New York, 10128, United States
PKM consists of a set of validated and computerized algorithms to perform the following steps:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The subject's serum calcium and phosphorus values will be input into PKM in order to determine the required PhosLo prescription. The prescription is determined as the number of gelcaps per day that must be taken by the subject.
If PKM determines the number of PhosLo gelcaps per day to be greater than or equal to the subject's current prescription, then PKM will calculate the current Ca++ and phosphate balance. Furthermore, the PKM algorithm will determine the additional number of PhosLo gelcaps needed to achieve neutral phosphate (P) balance with serum P reduced to 5.5 mg/dL.
The PKM algorithm also calculates the total P intake between dialyses and along with ePCR also calculates a Phosphorus/Protein Ratio (PPR). This ratio ranges from 8 to 14 in dialysis patients following a renal diet.
Time frame: 6 months
The primary outcome variable is the change in serum phosphorus between a baseline period and the latest value of the intervention period.
Fresenius Medical Care North America
Industry
Acronym: PKM2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04456803
Chronic Disease, Disease Attributes
Baotou, China
View Trial DetailsNCT03984760
Chronic Disease, Disease Attributes
Baotou, China
View Trial DetailsNCT01503736
Chronic Disease, Disease Attributes
Kaohsiung City, Taiwan
View Trial DetailsNCT01554982
Chronic Disease, Disease Attributes
Los Angeles, California, United States
View Trial Details